amg - The Stent Company

 Welcome at Home of Interventional Cardiology

amg International GmbH develops, manufactures and sells on a world-wide basis stents, stent implantation systems and balloon catheters as well as auxiliary products such as guide wires and inflation devices.

Over the years amg International GmbH became globally acknowledged for being specialized in manufacturing and marketing of high quality products made of extraordinary innovative technology.

This branch of cardiology deals specifically with the catheter based treatment of structural heart diseases, like deployment of stents and balloon catheters through a small hole made into a major artery, leaving no scars, which has given it the name "pin-hole surgery" (as opposed to "key-hole surgery").

The main advantages of using the interventional cardiologic approach is the avoidance of relative risk associated with open heart surgeries like, coronary artery bypass graft (CABG) where long postoperative morbidity is associated. Additionally, the interventional cardiology procedure of primary angioplasty is now the gold standard of care for an acute myocardial infarction.

The appearance of amg stent products can be seen as equivalence towards medical demand. As reminder, amg was worldwide the first company which has introduced a stent made entirely of a cobalt-chromium alloy to the market and can be seen as logical consequence according to amg’s vision and mission. This novelty was a further step forward allowing for implanting stents of smooth and subtle design with elegant and thinner stent struts as what has been done before.

amg’s vision:

“To become a global cardiology company through the design, development and commercialization of new innovative technologies, successfully compete in the coronary and peripheral stent market through a continuous flow of innovative development products and continue amg’s successful geographical expansion worldwide.”


amg’s mission:

“Improve patient care by the development and commercialization of new innovative technologies through the vision and assistance of a global advisory board and their colleagues.”

Furthermore, the company initiated various projects focused on the development of different biodegradable technologies, drug device combination products, and catheter technologies as part of its diversification strategy.